Purdue Team Develops Promising Allogeneic Treatment for Glioblastoma

Researchers at Purdue University are making significant strides in the fight against glioblastoma, an almost always lethal form of brain cancer with a median survival time of just 14 months. Traditional cancer treatments like chemotherapy and immunotherapy have proven largely ineffective against this devastating disease, prompting the Purdue team to develop a novel and innovative immunotherapy approach. 

Led by Sandro Matosevic, senior author on the study published in Nature Communications, the Purdue researchers have developed a patent-pending treatment that utilizes genetically engineered, fully off-the-shelf or allogeneic immune cells. Unlike traditional autologous cell therapies, which use the patient's own cells, the Purdue team's approach sources the immune cells from induced pluripotent stem cells, eliminating the need for blood cells and allowing for the creation of an unlimited supply of these potent cells.

In preclinical studies conducted on mice bearing human brain tumors, the Purdue team's engineered immune cells demonstrated remarkable efficacy, completely eliminating the growth of the tumors. Matosevic noted that this is a significant breakthrough, as one of the major hurdles in translating cell-based therapies to humans has been the poor expansion and lack of potency of patient-sourced cells.

With the success of their preclinical trials, the Purdue researchers are now focused on the next step: conducting clinical trials to treat patients with brain tumors, including those that were not successfully eliminated by surgery. Matosevic and his team are working closely with neurosurgical clinician collaborators to secure funding and initiate the necessary clinical protocols.